Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded to Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) from a hold rating to a sell rating in a research note published on Saturday.

ZNTL has been the topic of several other research reports. Wells Fargo & Company started coverage on Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price target on the stock. Guggenheim reiterated a “buy” rating and set a $6.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $5.17.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL opened at $2.10 on Friday. The company has a 50-day simple moving average of $2.57 and a 200-day simple moving average of $1.94. Zentalis Pharmaceuticals has a 52 week low of $1.01 and a 52 week high of $3.95. The firm has a market capitalization of $151.73 million, a P/E ratio of -1.11 and a beta of 1.71.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Thursday, March 26th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.08). As a group, equities analysts forecast that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Insiders Place Their Bets

In other news, major shareholder Group Walters bought 6,459,973 shares of the company’s stock in a transaction dated Wednesday, December 31st. The stock was bought at an average price of $1.20 per share, for a total transaction of $7,751,967.60. Following the completion of the transaction, the insider directly owned 13,509,973 shares in the company, valued at $16,211,967.60. The trade was a 91.63% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Vincent Vultaggio sold 29,951 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $2.43, for a total value of $72,780.93. Following the completion of the transaction, the insider owned 156,779 shares in the company, valued at approximately $380,972.97. This represents a 16.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 46,617 shares of company stock worth $113,417 over the last quarter. Corporate insiders own 1.90% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Sivia Capital Partners LLC acquired a new position in Zentalis Pharmaceuticals during the 4th quarter valued at about $27,000. Qube Research & Technologies Ltd acquired a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $37,000. Corient Private Wealth LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $41,000. Voleon Capital Management LP bought a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth approximately $41,000. Finally, SG Americas Securities LLC raised its stake in shares of Zentalis Pharmaceuticals by 35.3% during the third quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock worth $48,000 after buying an additional 8,236 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.